Kulkarni S G, Pegram A A, Smith P C
Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599, USA.
AAPS PharmSci. 2000;2(2):E18. doi: 10.1208/ps020218.
Drug treatment poses a therapeutic challenge in cystic fibrosis (CF) because the disposition of a number of drugs is altered in CF. Enhanced clearance of acetaminophen (APAP) and indocyanine green (ICG) have previously been reported in CF patients. The objective of the current study was to investigate if the CF-knockout mouse model (cftr(m1UNC)) shows altered pharmacokinetics similar to those seen in CF patients using the 2 model compounds APAP and ICG. Clearance (CL/F) of APAP and renal (CLR) and formation (CLf) clearance of acetaminophen glucuronide (AG) and acetaminophen sulfate (AS) were determined in CF-knockout mice following administration of APAP (50 mg/kg, intraperitoneal). CLR of AS was 19.5 and 12.9 (mL/min per kg) and CLf of AS was 10.4 and 6.7 mL/min per kg for homozygous and heterozygous males, respectively, which was significantly different between groups. CLR of AG was 6.3 and 4.8 mL/min per kg and CLf of AG was 9.6 and 8.9 mL/min per kg for homozygous and heterozygous males, respectively, although not reaching statistical significance. No significant differences were noted in either ClR or CLf of AG and AS in female CF mice. Plasma concentrations of ICG (10 mg/kg, intravenous) were determined over 0 to 15 minutes. Homozygous females showed a higher apparent volume of distribution (96 mL/kg) relative to heterozygous females (72 mL/kg). Similar to CF patients, a trend toward a lower Cmax was noted in homozygous male and female mice. However, contrary to human data, no significant differences in CL of ICG were noted. These results suggest that the CF-knockout mice have potential as a model for studying altered drug disposition in CF patients.
药物治疗在囊性纤维化(CF)中构成了一项治疗挑战,因为多种药物的处置在CF中会发生改变。先前已有报道称,CF患者对乙酰氨基酚(APAP)和吲哚菁绿(ICG)的清除增强。本研究的目的是使用两种模型化合物APAP和ICG,调查CF基因敲除小鼠模型(cftr(m1UNC))是否表现出与CF患者相似的药代动力学改变。在给予APAP(50 mg/kg,腹腔注射)后,测定CF基因敲除小鼠中APAP的清除率(CL/F)以及对乙酰氨基酚葡萄糖醛酸苷(AG)和对乙酰氨基酚硫酸盐(AS)的肾清除率(CLR)和生成清除率(CLf)。纯合子和杂合子雄性小鼠中AS的CLR分别为19.5和12.9(mL/min per kg),AS的CLf分别为10.4和6.7 mL/min per kg,两组之间存在显著差异。纯合子和杂合子雄性小鼠中AG的CLR分别为6.3和4.8 mL/min per kg,AG的CLf分别为9.6和8.9 mL/min per kg,尽管未达到统计学显著性。雌性CF小鼠中AG和AS的CLR或CLf均未观察到显著差异。在0至15分钟内测定静脉注射ICG(10 mg/kg)后的血浆浓度。相对于杂合子雌性小鼠(72 mL/kg),纯合子雌性小鼠表现出更高的表观分布容积(96 mL/kg)。与CF患者相似,纯合子雄性和雌性小鼠中观察到Cmax有降低的趋势。然而,与人类数据相反,ICG的CL未观察到显著差异。这些结果表明,CF基因敲除小鼠有潜力作为研究CF患者药物处置改变的模型。